Skip to main content
2024 ASCRS Annual Scientific Meeting Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
CME
CME
Invitation/Ticketed Event
Invitation/Ticketed Event
Invited Lectureship
Invited Lectureship
Award Recipient
Award Recipient
Live Streamed Session
Live Streamed Session
Nurses Contact Hours
Nurses Contact Hours
Self-Assessment
Self-Assessment
Back

Session: ePoster Monitor 2-Colon and Colorectal Cancer

eP123 - Local Excision for Stage 1 Rectal Cancer Results in Organ Preservation Without Compromising Cancer Outcomes

Sunday, June 2, 2024
8:18 AM – 8:23 AM ET, USA
Location: Baltimore Convention Center, Room 318-320

    ePoster Presenter(s)

  • Yuchen You, DO

    Resident
    community memorial hospital
    Ventura County Medical Center
    Monrovia, CA, United States

    All of the relevant financial relationships listed below have been mitigated.
    This individual has no financial relationships with ineligible companies.

    • Author(s)

  • KJ

    Karim Jreije, DO

    Author
    Ventura County Medical center
    Ventura, California, United States

    Disclosure information not submitted.

Purpose/Background: Surgery remains the mainstay of treatment for Stage 1 rectal cancer. Over the last two decades, the treatment paradigm for early-stage rectal cancers has trended towards organ preservation because of the impact of radical surgery on the overall quality of life. However, oncological adequacy, and survival outcomes, of less invasive techniques remain controversial. This study evaluates our recent institutional experience and compares oncologic outcomes in patients with Stage I rectal cancer treated with Local Excision (LE) versus Abdominal Surgery (AS).Methods/Interventions: Patients with clinical T1N0 or T2N0 rectal cancer were identified from the institutional colorectal registry. Demographic, clinical, treatment, and survival data were abstracted from the medical records.Results/Outcomes: 84 patients were treated between 2008 – 2022. The mean follow-up was 33 months. 47 patients were in AS, and 37 were in LE groups. 29 stomas were created in the AS group, and 7 were end colostomies. None of the patients in the LE group were treated with a stoma. Overall, 7 patients developed recurrence with distant metastases (n = 5) and locoregional recurrence (n = 2). The 5-year Overall Survival (OS) was 89% for LE and 85% for AS (p = 0.39). 5-year Disease-Specific Survival (DSS) was 89% for LE and 100% for AS (p=0.94).Conclusion/

Discussion: Cancer outcomes such as DSS and OS after LE for Stage I rectal cancer are comparable in patients treated with AS or LE while no patient in the LE group underwent stoma creation. Therefore, LE is an acceptable option given organ preservation, decreased morbidity, and comparable DSS and OS.Survival graphsDisease-Specific, Overall, and Recurrence-Free Survival probability by Surgery